Haleon wins Thorne bid interest, shares trade on LSE focus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 11:43.

Haleon (GB00BMX86B70) is back on the market’s radar in London after reports linked the consumer healthcare group to Thorne. Reuters reported the bid interest, while Haleon shares also trade with a clear analyst backdrop on the FTSE 100.

Reuters puts Thorne in view

Reuters said Haleon has entered the bidding process for Thorne, a dietary supplements maker, as the sales process moves ahead. The report gives the stock a concrete corporate angle and keeps the focus on deal logic rather than headline noise. Reuters UK coverage

MarketScreener currently shows Haleon at 345.95 GBX in London, down 0.67 percent on the day and 3.86 percent higher over five days. The same page lists a median target of 4.136 GBP and a reported gap of 18.76 percent versus that midpoint. MarketScreener consensus snapshot

Analysts keep a lid on it

Analyst commentary has stayed active in June, with JPMorgan reiterating a Sell view on 24 June and Rothschild & Co Redburn cutting the shares to Neutral on 18 June, both cited by MarketScreener. That keeps Haleon inside a cautious research setup even as the Thorne process adds a live corporate storyline. Recent analyst notes on MarketScreener

How Haleon makes money

Haleon sells consumer health products such as Sensodyne toothpaste, Panadol pain relief and Advil-branded medicines in selected markets. The business model centers on branded over-the-counter healthcare, oral health and vitamins.

London price check

The Haleon shares (GB00BMX86B70) trade on the London market in sterling. MarketScreener showed the stock at 345.95 GBX on 2026-06-29, 11:12 UTC.

Disclaimer: This article is for information only and is not investment advice.